Diligence memo · auto-generated · as of July 2, 2026
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Immune-Onc Therapeutics, Inc. operates in Biotechnology, based in PALO ALTO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immune-Onc Therapeutics, Inc. has raised $7.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.0M on 2016-07-01.
Most recent recorded round closed around 2016-07-01.
Valuation (modeled)modeled
Provath models Immune-Onc Therapeutics, Inc. at approximately $253M (range $7.6M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.20× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 50% of Biotechnology peers (4293 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.